论文部分内容阅读
目的观察羟基脲治疗重症β-地中海贫血患儿的疗效并且对其不良反应进行评估。方法对15例重症β地中海贫血患儿应用羟基脲[10~20mg/(kg·d]治疗,治疗期间对患儿全血细胞计数、血红蛋白F、肝肾功能进行监测,治疗后6个月对疗效进行评估。结果治疗后5个月患儿血红蛋白及血红蛋白F较治疗前明显升高(72·5±6·1)vs(93·6±11·9),(45·58±15·79)vs(73·37±23·89),P<0·05;而网织红细胞值明显降低(32·17±10·74)vs(15·87±7·29),P<0·05。治疗期间未见明显的不良反应。结论羟基脲可改善重症β-地中海贫血患儿的贫血状态且无明显的不良反应。
Objective To observe the curative effect of hydroxyurea on children with severe β-thalassemia and evaluate its adverse reactions. Methods Fifteen children with severe β-thalassemia were treated with hydroxyurea (10 ~ 20 mg / (kg · d)]. The whole blood count, hemoglobin F and liver and kidney function were monitored during the treatment. After 6 months of treatment, .Results Hemoglobin and hemoglobin F in children at 5 months after treatment were significantly higher than those before treatment (72 · 5 ± 6 · 1) vs (93 · 6 ± 11 · 9), (45 · 58 ± 15 · 79) vs (73.37 ± 23.89), P <0.05, while the reticulocyte count decreased significantly (32.17 ± 10.74) vs (15.87 ± 7.29), P <0.05. No significant adverse reactions were observed during the treatment.Conclusion Hydroxyurea can improve the anemia in children with severe β-thalassemia and has no obvious adverse reactions.